Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / HIST1H2BC



This biomarker is also known as:
  • H2B/a,
  • dJ221C16.3,
  • Histone H2B.a,
  • histone H2B type 1-C/E/F/G/I,
  • H2B/l,
  • H2B/h,
  • Histone H2B.k,
  • Histone H2B.l,
  • H2BFH,
  • histone cluster 1, H2bc,
  • H2B histone family, member L,
  • H2BFL,
  • histone H2B.l,
  • H2B/k,
  • H2BFK,
  • H2B.1,
  • histone 1, H2bc,
  • H2BFG,
  • Histone H2B.g,
  • H2B/g,
  • histone H2B.1 A,
  • Histone H2B.h,
  • Histone H2B.1 A,
  • H2BFA,

View in BioMuta


histone cluster 1, H2bc


QA State: Curated
Type: Gene
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Curated


No additional prostate data available.

Performance Comment

Significance Analysis of Microarray (SAM) was used to develop a 7-gene classifier. The overall prediction accuracy and sensitivity is 71% and 76%, respectively. The inclusion of the Gleason sum to the seven-gene classifier raised the prediction accuracy and sensitivity to 83% and 76% respectively This prognostic signature is closely associated with biochemical recurrence in patients after radical prostatectomy. The seven genes are: RRAGD, PQBP1, HIST1H2BC, ALDH1A2, TRIM22, RBPMS, HSPB8.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.